As you may be aware, some business combinations with special purpose acquisition companies (SPACs) have not gone well. But one exception — at least so far — is eFFECTOR Therapeutics (NASDAQ:EFTR) and EFTR stock. Source: Shutterstock This clinical-stage biotechnology firm focuses on selective translation regulation inhibitors (STRIs) in cancer. EFTR stock is currently up some…

Special purpose acquisition companies (SPACs) can be exciting to invest in, though there are always risks involved. This should definitely be kept in mind with eFFECTOR Therapeutics (NASDAQ:EFTR), as EFTR stock recently debuted on the Nasdaq Exchange in the wake of a SPAC merger. Source: Pasuwan/ShutterStock.com Not long ago, InvestorPlace contributor Samuel O’Brient provided the details on…

Today, another recent de-SPAC (special purpose acquisition company) Helbiz (NASDAQ:HLBZ) is seeing a lot of volatility. After declining 23% this morning at its lows, shares of HLBZ stock have more than rebounded, climbing 5% over yesterday’s close at the time of writing. Source: Shutterstock This incredible move is one that has made many investors’ heads…

Today, eFFECTOR (NASDAQ:EFTR) is a stock that’s once again in focus for investors. Indeed, the weekly chart on EFTR stock is absolutely incredible. Source: luchschenF / Shutterstock.com Yesterday, this stock was a top gainer in the markets, closing 50% higher over Friday’s close. Today, this stock is once again significantly higher. Today’s gain of more than…

Kadmon Holdings (NASDAQ:KDMN) stock is rising higher on Wednesday following news of a deal with Sanofi (NASDAQ:SNY). Source: Shutterstock.com The big news pushing KDMN stock higher today is Sanofi announcing plans to acquire the company. This will have it paying $9.50 per share for the company’s stock, which comes to a total of roughly $1.9…